Multiple Myeloma

Promising data reported from STR dosimetry study at ASCO meeting

Published in Blood Weekly, July 8th, 2004

NeoRx Corp. (NERX), a cancer therapeutics development company, presented data from its phase II dosimetry study of STR (skeletal targeted radiotherapy) in patients with multiple myeloma at the 2004 annual meeting of the American Society of Clinical Oncology (ASCO) on June 6 in New Orleans, Louisiana.

The data demonstrated positive trends in both patient response and safety. NeoRx is developing STR for use with high-dose chemotherapy and stem-cell transplantation. The company recently initiated a phase III pivotal study of STR in multiple myeloma, a cancer that arises in the bone marrow.

Of the 10 evaluable patients treated in the dosimetry study, 2...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2004-07-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry